Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Inflammatory Agents

Paclitaxel

Albumin-Bound Paclitaxel

Capecitabine

Cyclophosphamide

Triamcinolone

Triamcinolone Acetonide

Triamcinolone hexacetonide

Triamcinolone diacetate

Epirubicin

Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.

Standard chemotherapy (TA or TAC) followed by no more chemotherapy

Taxol, Epirubincin, with or without Cyclophosphamide

TA or TAC

Yan Lin, Doctor

The study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of standard chemotherapy versus standard chemotherapy followed by capecitabine as prolonged postoperative adjuvant treatment for breast cancer patients.

Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer

A Randomized, Phase II Study Comparing Standard Chemotherapy (TA-Taxol+Epirubicin or TAC-Taxol+Epirubicin+Cyclophosphamide) With Standard Chemotherapy (TA or TAC) Followed by Capecitabine (X) as Prolonged Postoperative Adjuvant Treatment for Breast Cancer

Peking Union Medical College Hospital

Chief of Dept. Breast Surgery, Professor

Carcinoma

Kevin A Camphausen, M.D.

Patients with biopsy proven breast cancer, clinical stage I and II, will be randomized to receive treatment by one of two methods: (1) total mastectomy and axillary dissection; or (2) excisional biopsy, axillary dissection, and definitive irradiation.

Data from single institutions and from retrospective comparisons suggest that definitive irradiation with cosmetically acceptable breast preservation offers survival and local control results equivalent to extirpative surgery. This study will test this hypothesis in a prospective, randomized manner. After primary therapy, subjects will be followed for: (1) survival; (2) sites of recurrence; (3) anatomic function; (4) complications of therapy; and (5) cosmesis.

The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation

The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection vs. Excisional Biopsy Axillary Dissection, and Definitive Irradiation

To compare the results of excisional biopsy followed by radiation therapy versus modified radiacal mastectomy

National Cancer Institute (NCI)

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Thromboembolism

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Stereotactic body radiation therapy for localized NSCLC

Stefan S Jeppesen, MD, PhD

The risk of thromboembolism is elevated in lung cancer patients. The present project investigates whether stereotactic body radiation therapy (SBRT) further increases the risk of thromboembolic disease in lung cancer patients.

If coagulation is activated by SBRT, this study could form the basis of new clinical trials investigating whether lung cancer patients may benefit from thromboprophylaxis during and after stereotactic body radiation therapy.

In this study, the patients will have blood samples drawn three times (prior to start of stereotactic body radiation therapy, immediately after stereotactic body radiation therapy completion, four to six weeks after completing stereotactic body radiation therapy). The blood sample at the completion of stereotactic body radiation therapy is an extra compared to normal gathering of blood samples of patients with NSCLC treated with stereotactic body radiation therapy. Also extra glasses with blood will be gathered at each blood sample for storage in a biobank in order to be able to make future analysis on this material.

There is a minimal risk of developing infection or hematoma in connection with blood sampling but we consider this risk to be negligible. The total volume of 120 ml blood drawn over a period of 6 weeks is an inconsiderable risk for the patient.

Coagulation System In STereotactic Radiotherapy Of NSCLC

Impact of Stereotactic Body Radiation Therapy on the Coagulation System in Patients With Non-small Cell Lung Cancer

Odense University Hospital

MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer	NCT02842099	Breast Cancer	TA or TAC X	18 Years - 70 Years	Peking Union Medical College Hospital
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation	NCT01468883	Breast Cancer	M X	18 Years -	National Institutes of Health Clinical Center (CC)
Coagulation System In STereotactic Radiotherapy Of NSCLC	NCT03893461	Thromboembolism Lung Cancer NSCLC Radiotherapy; C...	x	18 Years -	Odense University Hospital
Coagulation System In STereotactic Radiotherapy Of NSCLC	NCT03893461	Thromboembolism Lung Cancer NSCLC Radiotherapy; C...	x	18 Years -	Odense University Hospital

Spots Global Cancer Trial Database for x

Every month we try and update this database with for x cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for x

Every month we try and update this database with for x cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for x cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.